While this condition can be caused by diabetes, tissue disease and neurological disorders, which damage the nerves and blood ...

We recently compiled a list of the 13 Best Dividend Growth Stocks With 10%+ Yearly Increases. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of diabetes and obesity, while also delivering other health benefits, such as ...

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be short-lived deal ...

According to Bank of America, several companies are prime candidates for a stock split in the near future, which could lead to shares doubling the average market return, if historical trends are any ...

Prescriptions of obesity management drugs have increased, and these increasing trends are associated with online search trends.

Earnings season is when investors get a progress report about the companies in their portfolio or on their watchlist. An earnings report is generally a lagging indicator. That’s because the headline ...

Telehealth company Hims & Hers is pushing the boundaries of drug compounding and testing the limits of regulators.

MONDAY, Feb. 10, 2025 (HealthDay News) -- Yes, rare cases of vision issues have arisen in people taking popular GLP-1 weight loss drugs, but the jury's out on whether the medications caused the eye ...

There are no studies documenting the percentage of doctors taking the drugs. But physicians “are a good litmus test for drugs ...

Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.